• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Costs of major complications in people with and without diabetes in Tasmania, Australia
ConclusionsDiabetes complications are costly, and the costs are higher in people with diabetes than without diabetes. Our results can be used to populate diabetes simulation models and will support policy analyses to reduce the burden of diabetes.PMID:36375176 | DOI:10.1071/AH22180
Source: Australian Health Review - November 14, 2022 Category: Hospital Management Authors: Ngan T T Dinh Barbara de Graaff Julie A Campbell Matthew D Jose Burgess John Timothy Saunder Alex Kitsos Nadine Wiggins Andrew J Palmer Source Type: research

U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Acute kidney injury and risk of cardiovascular outcomes: A nationwide cohort study
CONCLUSION: Non-selected patients aged 50 years or above with AKI during admission had significantly higher one-year risk of cardiovascular event or death, especially, but not only due to heart failure, independent of age and eGFR.PMID:36210122 | DOI:10.1016/j.nefroe.2022.06.003
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - October 9, 2022 Category: Urology & Nephrology Authors: Philip Andreas Schytz Paul Blanche Anders Bonde Nissen Christian Torp-Pedersen Gunnar H Gislason Karl Emil Nelveg-Kristensen Kristine Hommel Nicholas Carlson Source Type: research

Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
CONCLUSIONS: HIF stabiliser management of anaemia had uncertain effects on CV death, fatigue, death (any cause), CV outcomes, and kidney failure compared to placebo or ESAs. Compared to placebo or ESAs, HIF stabiliser management of anaemia probably decreased the proportion of patients requiring blood transfusions, and probably increased the proportion of patients reaching the target Hb when compared to placebo.PMID:36005278 | DOI:10.1002/14651858.CD013751.pub2
Source: Cochrane Database of Systematic Reviews - August 25, 2022 Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Allison Jaure Elisabeth M Hodson Marinella Ruospo Tess E Cooper Deirdre Hahn Valeria M Saglimbene Jonathan C Craig Giovanni Fm Strippoli Source Type: research

What to Know About High Cholesterol in Kids
Heart disease is the leading cause of death in the U.S., but it’s not something we usually associate with kids. In many cases, however, the seeds of heart attacks and strokes may be sown in childhood. That’s because high or abnormal cholesterol levels, which are a major risk factor for heart disease and stroke, are not uncommon in kids. “People may feel that cholesterol is mostly an adult issue, which is not correct,” says Dr. Nivedita Patni, a pediatric endocrinologist at Children’s Health in Dallas and an assistant professor of pediatrics at UT Southwestern Medical Center. About 1 in 5 child...
Source: TIME: Health - July 13, 2022 Category: Consumer Health News Authors: Sandeep Ravindran Tags: Uncategorized freelance healthscienceclimate heart health Source Type: news

A population cohort analysis of English transplant centers indicates major adverse cardiovascular events after kidney transplantation.
Major adverse cardiovascular event (MACE) rates immediately after kidney transplantation remain uncertain due to heterogeneous reporting in the literature. To clarify this, we retrospectively studied every eligible kidney transplant procedure performed in England between April 1, 2002 and March 31. 2018 with follow-up through August 31, 2019. The primary outcome of interest was MACE broadly defined as any hospital admission with myocardial infarction, stroke, unstable angina, heart failure, any coronary revascularisation procedure and/or any cardiovascular death.
Source: Kidney International - June 15, 2022 Category: Urology & Nephrology Authors: Benjamin Anderson, Muhammad Qasim, Felicity Evison, Suzy Gallier, Jonathan N. Townend, Charles J. Ferro, Adnan Sharif Tags: clinical investigation Source Type: research

CZecking heart failure in patients with advanced chronic kidney disease (Czech HF-CKD): Study protocol
DISCUSSION: This trial will differ from others by: (1) detailed repeated hemodynamic assessment including arteriovenous access flow and (2) by careful assessment of adequate hydration to avoid confusion between HF and water overload.PMID:35676802 | DOI:10.1177/11297298221099843
Source: The Journal of Vascular Access - June 9, 2022 Category: Surgery Authors: Jan Malik Anna Valerianova Satu Sinikka Pesickova Zdenka Hruskova Vladimira Bednarova Pavel Michalek Vladimir Polakovic Vladimir Tesar Source Type: research

Myocardial infarction and factor VIII elevation in a 36-year-old man
We report a 36-year-old man who had a myocardial infarction despite lacking traditional cardiac risk factors. He developed end-stage heart failure and renal insufficiency necessitating a HeartMate II left ventricular assist device (LVAD). While on the transplant list, he experienced two episodes of LVAD thrombosis 6 months apart, prompting device exchange and escalation of anticoagulation therapy. He eventually underwent a successful heart-kidney transplant before suffering an extensive left lower extremity deep vein thrombosis 6 weeks later. A thrombophilia workup revealed elevated factor VIII activity of 319% (normal ran...
Source: Baylor University Medical Center Proceedings - December 31, 2021 Category: Universities & Medical Training Authors: Amit Alam Harsh Doshi Divya N Patel Keval Patel Dreamy James Jesus Almendral Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10